Literature DB >> 11112897

Glucocorticoids preferentially upregulate functional CXCR4 expression in eosinophils.

H Nagase1, M Miyamasu, M Yamaguchi, H Kawasaki, K Ohta, K Yamamoto, Y Morita, K Hirai.   

Abstract

BACKGROUND: Chemokines play an important role in accumulation of eosinophils at allergic inflammatory sites. Systemic administration of glucocorticoids (GCCs) attenuates tissue eosinophilia. In vivo chemokine actions are regulated at levels of both ligand production and receptor expression. The inhibitory effects of GCCs on the production of eosinophil-active chemokines, such as eotaxin, have been well established. However, no data exist regarding the effects of GCCs on expression of chemokine receptors in eosinophils per se.
OBJECTIVE: The objective of this study was to investigate the regulation of chemokine receptor expression in eosinophils by GCCs.
METHODS: Chemokine receptor expression was analyzed by using flow cytometry and reverse transcriptase PCR. Intracellular Ca(2+) influx and chemotaxis were also analyzed.
RESULTS: Eosinophil CCR3 expression was slightly downregulated by 24-hour treatment with dexamethasone (DEX). On the other hand, DEX-treated eosinophils showed markedly increased CXCR4 expression ( approximately 6 fold) in a time- and dose-dependent fashion. In contrast to eosinophils, CXCR4 expression in neutrophils was only marginally affected by DEX. In DEX-treated eosinophils, stromal cell-derived factor 1alpha, a natural ligand for CXCR4, induced a higher level of Ca(2+) influx and chemotaxis compared with untreated cells.
CONCLUSION: GCCs upregulate the expression of CXCR4 in eosinophils but not in neutrophils. Because stromal cell-derived factor 1alpha may play a role in baseline trafficking of eosinophils into extravascular tissues rather than recruiting them directly to inflammatory sites, upregulation of CXCR4 by GCCs may mediate the antiallergic property of these drugs by sequestering eosinophils from the circulation to extravascular tissues.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11112897     DOI: 10.1067/mai.2000.110923

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  13 in total

Review 1.  Eosinophils in innate immunity: an evolving story.

Authors:  Revital Shamri; Jason J Xenakis; Lisa A Spencer
Journal:  Cell Tissue Res       Date:  2010-11-03       Impact factor: 5.249

2.  Glucocorticoid-induced eosinopenia in humans can be linked to early transcriptional events.

Authors:  P Khoury; K Stokes; M Gadkari; M A Makiya; F Legrand; Z Hu; A Klion; L M Franco
Journal:  Allergy       Date:  2018-07-17       Impact factor: 13.146

3.  Murine Glucocorticoid Receptors Orchestrate B Cell Migration Selectively between Bone Marrow and Blood.

Authors:  Derek W Cain; Carl D Bortner; David Diaz-Jimenez; Maria G Petrillo; Amanda Gruver-Yates; John A Cidlowski
Journal:  J Immunol       Date:  2020-06-22       Impact factor: 5.422

4.  CXCR4 expression on monocytes is up-regulated by dexamethasone and is modulated by autologous CD3+ T cells.

Authors:  Jason Caulfield; Maria Fernandez; Vladimir Snetkov; Tak Lee; Catherine Hawrylowicz
Journal:  Immunology       Date:  2002-02       Impact factor: 7.397

5.  Il-1 beta-induced post-transition effect of NF-kappaB provides time-dependent wave of signals for initial phase of intrapostatic inflammation.

Authors:  Eugene V Vykhovanets; Sanjeev Shukla; Gregory T MacLennan; Olena V Vykhovanets; Donald R Bodner; Sanjay Gupta
Journal:  Prostate       Date:  2009-05-01       Impact factor: 4.104

Review 6.  The Eosinophil in Health and Disease: from Bench to Bedside and Back.

Authors:  Wei Liao; Hai Long; Christopher Chia-Chi Chang; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2016-04       Impact factor: 8.667

7.  Chemokine-mediated redirection of T cells constitutes a critical mechanism of glucocorticoid therapy in autoimmune CNS responses.

Authors:  Nils Schweingruber; Henrike J Fischer; Lisa Fischer; Jens van den Brandt; Anna Karabinskaya; Verena Labi; Andreas Villunger; Benedikt Kretzschmar; Peter Huppke; Mikael Simons; Jan P Tuckermann; Alexander Flügel; Fred Lühder; Holger M Reichardt
Journal:  Acta Neuropathol       Date:  2014-02-01       Impact factor: 17.088

8.  The glucocorticoid RU24858 does not distinguish between transrepression and transactivation in primary human eosinophils.

Authors:  Mirkka Janka-Junttila; Eeva Moilanen; Hannele Hasala; Xianzhi Zhang; Ian Adcock; Hannu Kankaanranta
Journal:  J Inflamm (Lond)       Date:  2006-07-12       Impact factor: 4.981

Review 9.  Eosinophils and eosinophil-associated disorders: immunological, clinical, and molecular complexity.

Authors:  Peter Valent; Lina Degenfeld-Schonburg; Irina Sadovnik; Hans-Peter Horny; Michel Arock; Hans-Uwe Simon; Andreas Reiter; Bruce S Bochner
Journal:  Semin Immunopathol       Date:  2021-05-30       Impact factor: 9.623

10.  An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in mice.

Authors:  François Daubeuf; Muriel Hachet-Haas; Patrick Gizzi; Vincent Gasparik; Dominique Bonnet; Valérie Utard; Marcel Hibert; Nelly Frossard; Jean-Luc Galzi
Journal:  J Biol Chem       Date:  2013-02-28       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.